Marvel BiosciencesTSXV: MRVL
Marvel Biosciences is a Calgary-based clinical-stage biotechnology company pursuing a 'drug redevelopment' strategy to create synthetic derivatives of approved drugs with improved therapeutic profiles. Its lead candidate MB-204, a fluorinated derivative of the adenosine A2a receptor antagonist Istradefylline, is advancing through IND-enabling pre-clinical studies targeting autism spectrum disorder, Rett syndrome, and depression, with Phase 1 trials expected to begin in Australia.
Development Programmes
1MB-204 (Fluorinated Istradefylline Derivative)
Rett syndrome / Fragile X syndrome / ASD / depression
Programme Tracker
Autism Spectrum Disorder (ASD)
IND-enabling studies complete; CRO selected (Novotech, Australia) for Phase 1; FDA Orphan Drug Designation filing planned for Rett syndrome; composition of matter patents granted in US, China, Japan
Milestones
preclinical-data
CompletedActual: Aug 1, 2023
Completed final FDA-required toxicology study for Phase 1 readiness
Why it matters: GLP tox completion means MB-204 has a complete preclinical safety package for IND filing. MB-204 is a fluorinated derivative of istradefylline (an adenosine A2A receptor antagonist already FDA-approved for Parkinson's disease as Nourianz). This is NOT a psychedelic/serotonergic compound — it works through adenosine receptor modulation.
Company milestone
CompletedActual: Mar 17, 2025
Announced plan to file FDA Orphan Drug Designation for MB-204 in Rett syndrome; preclinical data showed MB-204 outperformed Trofinetide (Daybue, the only FDA-approved Rett treatment)
Why it matters: Rett syndrome is a devastating rare neurodevelopmental disorder with only one approved treatment (Trofinetide/Daybue, which has significant GI side effects and modest efficacy). If MB-204 outperforms Trofinetide preclinically, ODD would provide 7-year market exclusivity, tax credits, and expedited review.
Company milestone
CompletedActual: Feb 3, 2026
Japanese Patent No. 2022-554855 granted for MB-204 composition of matter
Why it matters: Third major jurisdiction (after China and US) with composition of matter patent protection. Strong global IP position for MB-204.
Company milestone
CompletedActual: Mar 1, 2026
US Patent No. 12,570,656 B2 granted for MB-204 composition of matter
Why it matters: US composition of matter patent is the most commercially valuable IP protection. Completes the major-market patent trifecta (US, Japan, China).
Trial start
In progressActual: Mar 25, 2026
Selected Novotech (Australia) as CRO for Phase 1 clinical trial of MB-204
Why it matters: CRO selection is the final step before Phase 1 initiation. Australia chosen for >40% R&D tax credits under the CTN scheme. Phase 1 expected to start in 2026.
Funding milestone
CompletedActual: Mar 30, 2026
Secured $600K non-dilutive Alberta Innovates AICE grant for Phase 1 + NRC IRAP grant for liquid formulation development
Why it matters: Non-dilutive government grants fund Phase 1 and formulation work. Marvel trades on TSXV as MRVL. CEO/CSO is Dr Mark Williams.
Watch next: Phase 1 first patient dosed in Australia; ODD filing with FDA; Rett syndrome Phase 2 design
Recorded Events
Mar 30, 2026: Funding milestone
Mar 25, 2026: Trial start
Mar 1, 2026: Company milestone
Feb 3, 2026: Company milestone
Mar 17, 2025: Company milestone
Quick Facts
- Type
- Public Biotech
- Ticker
- TSXV: MRVL
- Lead Stage
- Pre-clinical
- Website
- Visit